A randomised, Stratified, Open Label, Phase II pilot study on the safety of a daily, intermittent or weekly administration of 1, 3 or 10mg/kg of AmBisome? in antifungal primary prophylaxis

  • Morrissey, Orla (Primary Chief Investigator (PCI))
  • Schwarer, Anthony (Chief Investigator (CI))

Project: Research

Project Details

StatusFinished
Effective start/end date4/12/071/09/15